Financial

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

Iovance cuts staff on slower cell therapy sales growth

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.

News

Lilly weakens on oral weight-loss drug data

Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.

News

Bayer's job cull nears 12,000, with more to come

The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – and isn't yet completed.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

GSK suffers a setback with its TIM-3 programme

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

CSL will slash headcount and hive off vaccine business

Iovance cuts staff on slower cell therapy sales growth

Lilly weakens on oral weight-loss drug data

Bayer's job cull nears 12,000, with more to come

Novo Nordisk weakens again on interim results readout

GSK suffers a setback with its TIM-3 programme

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Financial

Editor's Picks